Elevance Health stock heads into the open after a 1.7% drop
Published on 09/15/2026 at 05:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Elevance Health stock closed near USD 418.72 on the New York Stock Exchange on September 14, 2026, down about 1.7% from the prior session, according to recent market data for that date. The move left the shares lagging a Nasdaq Composite that gained roughly 1% on the same day, highlighting relative weakness in the name within a stronger technology-heavy benchmark.
September 14, 2026 in numbers
Elevance Health Inc. (ISIN US2855211023, NYSE: ELV) saw its shares trade around USD 418.72 as of September 14, 2026, per market data referenced in an article on recent performance.Ad-hoc-news noted that this price level reflects trading below some analyst targets, such as a USD 492 figure from Wells Fargo and close to a USD 424 target from RBC as of September 14, 2026. A separate market wrap reported that Elevance Health lost 1.73% in the latest session, placing it among health-care names that declined as equity futures retreated on worries about artificial intelligence spending and rising oil prices, which weighed on broader sentiment.Eurasia Business News In the same session, the Nasdaq Composite closed higher by about 1%, underscoring that Elevance Health underperformed a key equity benchmark despite the broader market advance.Zacks
Outlook for today, September 15, 2026
Company-specific events for Elevance Health today are not prominently highlighted in the latest publicly available earnings and corporate news over the past week, so the shares are set to trade largely in response to broader health-care sector moves and macro drivers as the new session begins. With recent commentary pointing to investor sensitivity around artificial intelligence investment trends and higher energy prices,Eurasia Business News overall market tone and movements in major indices such as the Nasdaq Composite may continue to influence Elevance Health stock today. The latest coverage also emphasizes that the shares remain below some updated analyst price targets following the company’s second-quarter 2026 earnings beat and guidance raise earlier in the quarter,Ad-hoc-news a backdrop that may shape how investors assess the stock’s valuation as trading resumes ahead of the opening bell.
